<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805879</url>
  </required_header>
  <id_info>
    <org_study_id>REB#19-0016</org_study_id>
    <nct_id>NCT04805879</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Major Depressive Disorder</brief_title>
  <official_title>A Clinical Trial to Evaluate the Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cumming school of medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The W. Garfield Westin Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goals of this proof of concept clinical trial are to determine the effectiveness,&#xD;
      safety and tolerability of oral FMT in adults with Treatment Resistant Depression (TRD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase 2/3, double-blinded, randomized controlled trial (RCT) in which 80&#xD;
      adults with TRD being treated with an approved antidepressant medication will be assigned to&#xD;
      either FMT capsules or identically appearing placebo capsules. Participant will be followed&#xD;
      for f for 14 weeks post FMT. This extended observation period will allow us to see, whether&#xD;
      FMT leads to sustainable improvements in depression and changes in intestinal microbiome&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2021</start_date>
  <completion_date type="Anticipated">March 4, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 4, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the MADRS total score</measure>
    <time_frame>from baseline (pre-intervention) to the final visit (week 13)</time_frame>
    <description>To evaluate the effectiveness of adjunct oral FMT as compared to placebo with currently accepted approved therapy for depression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects as reported on the Toronto Side Effect Scale (TSES)</measure>
    <time_frame>from baseline (pre-intervention) to the final visit (week 13)</time_frame>
    <description>The tolerability of FMT will be assessed using the Toronto Side effects Scale (TSES)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GI tolerability of patients with Irritable Bowel Syndrome (IBS)</measure>
    <time_frame>from baseline (pre-intervention) to the final visit (week 13)</time_frame>
    <description>GI tolerability will be assessed using the IBS Symptom Severity Scale (IBS SSS) and IBS specific Quality of Life (IBS-QoL) questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess the effect of FMT on microbiome profile</measure>
    <time_frame>from baseline (pre-intervention) to the final visit (week 13)</time_frame>
    <description>Changes will be assessed using next generation sequencing and nuclear magnetic resonance (NMR) spectrometry</description>
  </other_outcome>
  <other_outcome>
    <measure>changes in inflammatory markers (Blood)</measure>
    <time_frame>from baseline (pre-intervention) to the final visit (week 13)</time_frame>
    <description>To study the changes in inflammatory markers (blood CRP)</description>
  </other_outcome>
  <other_outcome>
    <measure>changes in inflammatory markers (stool)</measure>
    <time_frame>from baseline (pre-intervention) to the final visit (week 13)</time_frame>
    <description>To study the changes in inflammatory markers (fecal calprotectin)</description>
  </other_outcome>
  <other_outcome>
    <measure>changes in serum cytokines</measure>
    <time_frame>from baseline (pre-intervention) to the final visit (week 13)</time_frame>
    <description>To study the changes in serum cytokines (IL-6, IL-10, IL-8, IFNγ and TNF)</description>
  </other_outcome>
  <other_outcome>
    <measure>To examine imaging changes</measure>
    <time_frame>from baseline (pre-intervention) to the final visit (week 13)</time_frame>
    <description>examine imaging changes via a structural and functional neuroimaging scan associated with FMT</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Depression</condition>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>FMT capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each dose of FMT capsules consists of 20 capsules. The 20 over encapsulated capsules are derived from 100 grams of stool and each containing 0.67 ml of pelleted intestinal microbes.&#xD;
PArticipants will recieve a loading dose of 60 capsules over 3 consecutive days followed by a booster dose of 20 caspules 1 month after and a second similar booster dose a month after that</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral Capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo casules are inactive capsules that look and weigh the same as the Active FMT caspules. Participants will follow the same schedule as the Active arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FMT oral Capsules</intervention_name>
    <description>Each dose of FMT capsules consists of 20 capsules. The 20 over encapsulated capsules are derived from 100 grams of stool donated by a healthy indvidual that was screened to have no mental health issues or chronic or contagious doseases. Each capsule will contain 0.67 ml of pelleted intestinal microbes. Therefore it is considered that the 20 capsules are equivalent to 100 grams of stool</description>
    <arm_group_label>FMT capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo Capsules</intervention_name>
    <description>Placebo Capsules that will look and weigh the same as the FMT oral capsules.</description>
    <arm_group_label>Placebo oral Capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between 18-65 years of age:&#xD;
&#xD;
             Participants should be at least 18 years old and not older than 65 years at the day of&#xD;
             screening&#xD;
&#xD;
          2. Have a primary diagnosis of MDD according to the M.I.N.I. International&#xD;
             Neuropsychiatric Interview (MINI)47&#xD;
&#xD;
          3. Medical history suggestive of Treatment Resistant Depression (TRD). (inadequate&#xD;
             response to at least 2 approved antidepressants. at least one of which is in the&#xD;
             current episode of depression)48&#xD;
&#xD;
          4. Have been on a current treatment with a approved antidepressant at an adequate dose&#xD;
             for at least 8 weeks&#xD;
&#xD;
          5. A MADRS score of ≥ 19 at screening and visit 2&#xD;
&#xD;
        Additional Inclusion Criteria:&#xD;
&#xD;
        - Participants who will be included in the IBS-D cohort should have a confirmed diagnosis&#xD;
        of IBS-D as indicated by the referring gastroenterologist.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Participant meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5)1&#xD;
             Criteria for the following conditions according to the M.I.N.I: f) Substance Use&#xD;
             Disorder within the last 3 months. *(Criteria should include Alcohol and non-alcohol&#xD;
             substances except Cannabis) g) Moderate or severe Substance use disorder for Cannabis&#xD;
             use the last 3 months h) Active Anorexia Nervosa or Bulimia nervosa i) Schizophrenia&#xD;
             or schizoaffective disorder j) Active suicidality 2. Regular intake of non-steroidal&#xD;
             anti-inflammatory drugs, antibiotics, or iron supplements for medical purposes in the&#xD;
             3 months prior to study entry 3. Use of prebiotics or probiotics for medical purposes&#xD;
             for more than 2 weeks within the last 3 months 4. Clinically diagnosed chronic&#xD;
             gastrointestinal diseases (IBD, Crohn's disease, Ulcerative colitis, Celiac disease)&#xD;
             5. Conditions causing immune suppression 6. Not breastfeeding, pregnant or seeking to&#xD;
             get pregnant during the course of this study. Be using an acceptable method of birth&#xD;
             control (implants, injectable, combined oral contraceptives, IUDs, sexual abstinence&#xD;
             or a vasectomized partner) 7. Reported allergy to Vancomycin or Nitazoxanide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valerie Taylor, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cumming School of Medicine, University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Research Coordinator</last_name>
    <phone>403-210-8650</phone>
    <email>fmtmddstudy@ucalgary.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Research Manager</last_name>
    <phone>403-210-7282</phone>
    <email>fmtmddstudy@ucalgary.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cumming School of Medicine, University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4 Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Research Coordinator</last_name>
      <phone>403-210-8650</phone>
      <email>fmtmddstudy@ucalgary.ca</email>
    </contact>
    <contact_backup>
      <last_name>Asem Research Manager</last_name>
      <phone>403-210-7282</phone>
      <email>fmtmddstudy@ucalgary.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Valerie Taylor</investigator_full_name>
    <investigator_title>Head of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>FMT</keyword>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <keyword>Microbiome</keyword>
  <keyword>gut brain axis</keyword>
  <keyword>Major depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

